Double-Drug attack shows promise for tough head and neck cancers
NCT ID NCT03370276
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether combining two FDA-approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that has returned or spread. A total of 95 participants received the drug combination to find the best dose and see if it improves survival. The goal is to control the disease and extend life, not to cure it.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab and nivolumab (drug combination)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced head and neck cancer that has come back or spread.
What could go wrong
This is an early-phase trial (phase I/II), so results are preliminary. The combination may cause significant side effects and may not improve survival for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States